[EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT [FR] AGONISTES DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE, LEURS PROCÉDÉS DE PRÉPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT EN TANT QUE PRINCIPE ACTIF
[EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT [FR] AGONISTES DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE, LEURS PROCÉDÉS DE PRÉPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT EN TANT QUE PRINCIPE ACTIF
SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT
申请人:LG LIFE SCIENCES LTD.
公开号:US20150376173A1
公开(公告)日:2015-12-31
The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.
[EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT<br/>[FR] AGONISTES DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE, LEURS PROCÉDÉS DE PRÉPARATION, ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT EN TANT QUE PRINCIPE ACTIF
申请人:LG LIFE SCIENCES LTD
公开号:WO2014129796A1
公开(公告)日:2014-08-28
The present invention relates to novel compounds of Formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders.